Melasma: A review

Journal of Cutaneous Medicine and Surgery

Volumn 8, Issue 2, 2004, Pages 97-102

  Victor, Frank C ^a   Gelber, Jeremy ^a   Rao, Babar ^a,b  

^a ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

^b Clinical Academic Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZELAIC ACID; CORTICOSTEROID; GLYCOLIC ACID; HYDROQUINONE; KOJIC ACID; LIQUIRITIN; MELANIN; N ACETYL 4 S CYSTEAMINYLPHENOL; PHENOL DERIVATIVE; RETINOIC ACID; SUNSCREEN; UNCLASSIFIED DRUG;

CARBON DIOXIDE LASER; CHLOASMA; CLINICAL FEATURE; DISEASE CLASSIFICATION; ELECTRON MICROSCOPY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOCYTE; MELANOGENESIS; MELANOSOME; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKIN ABRASION; SKIN PIGMENTATION; SUN EXPOSURE; ULTRAVIOLET RADIATION;

EID: 2942648022     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1177/120347540400800204     Document Type: Review

References (33)

1. Fitzpatrick TB, Eisen A, Klaus W, et al. Dermatology in General Medicine3rd ed. McGraw-Hill, New York 1987, pp 848-849.
2. Kang WH, Yoon KH, Lee E-S, et al. Melasma: histopathological characteristics in 56 Korean patients Br J Dermatol 2002; 1462:228-237.
3. Sanchez NP, Pathak MA, Sato S, et al. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study J Am Acad Dermatol 1981; 46:698-710.
4. Grimes PE. Melasma. Etiologic and therapeutic considerations Arch Dermatol 1995; 13112:1453-1457.
5. Pandya AG, Guevara IL. Disorders of Hyperpigmentation Dermatol Clin 2000; 181:91-98.
6. Lufti RJ, Fridmanis M, Misrunas AL, et al. Association of melasma with thyroid autoimmunity and other thyroidal abnormalities and their relationship to the origin of melasma J Clin Endocrinol Metab 1985; 61:28-31.
7. Resnick S. Melasma induced by oral contraceptive drugs. JAMA 1967; 199:95-99.
8. Sturm RA, Duffy DL, Box NF, et al. The role of melanocortin-1 receptor polymorphism in skin cancer risk phenotypes. Pigment Cell Res 2003; 163:266-272.
9. Sarangarajan R, Boissey RE. Tyrp I and oculocutaneous albinism type 3 Pigment Cell Res 2001; 146:437-444.
10. Suzuki I, Kato T, Motokawa T, et al. Increase of pro-opiomelanocortin mRNA prior to tyrosinase, tyrosinase-related protein 1, dopachrome tautomerase, Pmel-17/gp 100, and P-protein mRNA in human skin after ultraviolet B irradiation J Invest Dermatol 2002; 1181:73-78.
11. Im S, Moro O, Peng F, et al. Activation of cyclic AMP pathway by alpha-melanotropin mediates the response of human melanocytes to ultraviolet B radiation Cancer Res 1998; 58(1):47-54.
12. Im S, Kim J, On XV, et al. Increased expression of [alpha]-melanocyte stimulating hormone in the lesional skin of melasma. Br J Dermatol 2002; 1461:165-167.
13. Perez M, Sanchez JL, Aguilo F. Endocrinologic profile of patients with idiopathic melasma J Invest Dermatol 1983; 816:543-545.
14. Sialy R, Hassan I, Kaur I, et al. Melasma in men: a hormonal profile J Dermatol 2000; 271:64-65.
15. Wolf R, Matz H, Orion E, et al. Sunscreens - The Ultimate Cosmetic Acta Dermatovenerol Croat 2003; 113:158-162.
16. Perez-Bernal A, Munoz-Perez MA, Camacho F. Management of facial hyperpigmentation Am J Clin Dermatol 2000; 15:261-268.
17. Levin CY, Maibach H. Exogenous ochronosis. An update on clinical features, causative agents and treatment options Am J Clin Dermatol 2001; 24:213-217.
18. Tung RC, Bergfeld WF, Vidimos AT, et al. alpha-Hydroxy acid-based cosmetic procedures. Guidelines for patient management Am J Clin Dermatol 2000; 12:81-88.
19. Lim JT. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid Dermatol Surg 1999; 254:282-284.
20. Jimbow K. N-acetyl-4-S-cysteaminylphenol as a new type of depigmenting agent for the melanoderma of patients with melasma Arch Dermatol 1991; 12710:1528-1534.
21. Fitton A, Goa KL. Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders Drugs 1991; 415:780-798.
22. Schallreuter KU, Wood JW. A possible mechanism of action for azelaic acid in the human epidermis Arch Dermatol Res 1990; 2823:168-171.
23. Nazzaro-Porro M. Azelaic acid J Am Acad Dermatol 1987; 176:1033-1041.
24. Verallo-Rowell VM, Verallo V, Graupe K, et al. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma Acta Derm Venereol Suppl (Stockh) 1989; 143:58-61.
25. Balina LM, Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream Int J Dermatol 1991; 3012:893-895.
26. Yoshimura K, Tsukamoto K, Okazaki M, et al. Effects of all-trans retinoic acid on melanogenesis in pigmented skin equivalents and monolayer culture of melanocytes J Dermatol Sci 2001; 27Suppl 1:S68-75.
27. Griffiths CE, Finkel LJ, Ditre CM, et al. Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial Br J Dermatol 1993; 1294:415-421.
28. Amer M, Metwalli M. Topical liquiritin improves melasma Int J Dermatol 2000; 394:299-301.
29. Kligman AM, Willis I. A new formula for depigmenting human skin Arch Dermatol 1975; 1111:40-48.
30. Taylor SC, Torok H, Jones T, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma Cutis 2003; 721:67-72.
31. Javaheri SM, Handa S, Kaur I, et al. Safety and efficacy of glycolic acid facial peel in Indian women with melasma Int J Dermatol 2001; 405:354-357.
32. 2 laser followed by Q-switched alexandrite laser: a pilot study Dermatol Surg 1999; 256:494-497.
33. Kunachak S, Leelaudomlipi P, Wongwaisayawan S. Dermabrasion: a curative treatment for melasma Aesth Plast Surg 2001; 252:114-117.